Executive Summary

The century-long Japanese pharmaceutical innovator, Company X, had a challenge entering the Chinese market, competing against generic alternatives for their brand-name drug Y. Unibest's expertise helped them secure a regulatory certificate and identify a high-value niche market, resulting in a successful market entry and a new profit growth.

Customer Profile

Company X is a Japanese pharmaceutical company with a long-standing history. Their business focuses on essential and specialty medicines, and they consistently strive to innovate in the industry. Their portfolio includes a wide range of drugs, one of which is drug Y, that they sought to introduce and market in China.

The Challenges

As an innovator, Company X wanted to enter the Chinese market. However, they faced several challenges:

Limited experience and expertise in navigating the dynamic Chinese market, especially with recent changes in medical policy

Competition from domestic generic drugs for their drug Y

Uncertainties in the market and concerns about potential price pressure due to China's national medical insurance program

The Solutions

Unibest's FDF (Finished Dosage Form) arm provided a comprehensive market entry solution to Company X. This was divided into two main parts:

Figuring out how to enter the market, compete against generic drugs, and register as the reference drug for bioequivalence (BE) studies

Identifying a niche market to focus on, where patients are willing to pay higher prices for innovator drugs

The Implementation

Unibest's FDF team carried out the following tasks:

Successfully obtained a regulatory certificate for brand-name drug Y's API, allowing it to be registered as the reference drug for BE studies

Identified a niche market with patients having medical needs and the willingness to pay higher prices for innovator drugs, thereby dodging competition from generic alternatives

The Results

With Unibest's strategic market plan, Company X was able to:

Successfully enter the Chinese market with drug Y

Avoid direct competition from generic drug companies

Achieve a new profit growth and even secure a higher price for their drug in China compared to the Japanese market

Testimonial/Quote

"The Unibest team has helped us to enter the Chinese market with our brand-name drug Y, which faced direct competition with a generic drug company. We were also worried about the price pressure from the National Reimbursement Drug List, but thanks to Unibest's strategic market plan that gave drug Y an even higher price than its native Japanese market, we were able to avoid competition with the generic drug company. I am very grateful for all of the help and support that Unibest has given us." - Representative from Company X

Call-To-Action

Uncertain about how to enter the Chinese market? Schedule a meeting with us to discuss how Unibest can help you achieve success!